Halozyme Therapeutics, Inc. (NASDAQ:HALO)
CAPS Rating:
A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.
RSS Headlines
Fool UK
Recs
In the red on CAPS, green in the Fund. When HALO comes back around the $9.00 way I will re-assess the situation. Boo YAH : )